<DOC>
	<DOCNO>NCT02466425</DOCNO>
	<brief_summary>The study design evaluate efficacy safety SHP465 treatment ADHD child adolescent ( age 6-17 year ) . The primary objective study evaluate efficacy SHP465 administer daily morning dose compare placebo treatment child adolescent ( 6-17 year age inclusive ) diagnose ADHD .</brief_summary>
	<brief_title>Safety Efficacy Study SHP465 Children Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>1 . Subject must 617 year age , inclusive , time consent . 2 . Subject 's parent legally authorize representative ( LAR ) must provide signature informed consent , must documentation assent ( applicable ) subject indicate subject aware investigational nature study require procedure restriction accordance ICH GCP Guideline E6 ( 1996 ) applicable regulation complete studyrelated procedure . 3 . Subject parent/LAR willing able comply test requirement define protocol , include oversight morning dosing . Specifically , parent/LAR must available approximately 7:00AM ( Â±2 hour ) dispense dose investigational product study duration . 4 . Subject , female childbearing potential , must positive serum beta human chorionic gonadotropin pregnancy test Screening Visit ( Visit 1 ) must negative urine pregnancy test Baseline Visit ( Visit 2 ) agree comply applicable contraceptive requirement protocol . 5 . Subject must satisfactory medical assessment clinically significant relevant abnormality . 6 . Subject meet DSMIVTR criterion primary diagnosis ADHD base detailed psychiatric evaluation . 7 . Subject ADHDRSIV Total Score &gt; 28 Baseline Visit ( Visit 2 ) . 8 . Subject function ageappropriate level intellectually , determine study Investigator . 9 . Subject currently ADHD therapy , completely satisfied aspect current ADHD therapy . 10 . Subject able swallow capsule whole . 1 . Subject current , control ( medication prohibit study ) uncontrolled , comorbid psychiatric diagnosis significant symptom significant comorbid Axis II disorder significant Axis I disorder ( posttraumatic stress disorder , psychosis , bipolar illness , pervasive developmental disorder , severe obsessive compulsive disorder , depressive anxiety disorder ) symptomatic manifestation , opinion examine clinician , contraindicate treatment SHP465 confound efficacy safety assessment . Comorbid psychiatric diagnosis establish Screening Visit ( Visit 1 ) interview KSADSPL additional module warrant result initial interview . Subjects may continue participation behavioral modification program study long participate program least 1 month time Baseline Visit ( Visit 2 ) . 2 . Subject meet DSMIVTR diagnosis conduct disorder . Oppositional defiant disorder exclusionary . 3 . Subject consider suicide risk opinion Investigator , previously make suicide attempt , currently demonstrate active suicidal ideation . Subjects intermittent passive suicidal ideation necessarily exclude base assessment Investigator . 4 . Subject underweight base Centers Disease Control Prevention body mass index ( BMI ) forage sexspecific value Screening Visit ( Visit 1 ) . Underweight define BMI &lt; 3rd percentile 5 . Subject significantly overweight base Centers Disease Control Prevention BMIforage sex specific value Screening Visit ( Visit 1 ) . Significantly overweight define BMI &gt; 97th percentile study 6 . Subject concurrent chronic acute illness ( severe allergic rhinitis infectious process require antibiotic ) , disability , condition might confound result safety assessment conduct study might increase risk subject . Similarly , subject exclude additional condition ( ) , Investigator 's opinion , would prohibit subject completing study would best interest subject . The additional condition would include significant illness unstable medical condition could lead difficulty comply protocol . Mild , stable asthma exclusionary . 7 . Subject history seizure ( infantile febrile seizure ) , chronic current tic disorder , current diagnosis Tourette 's Disorder . Subject history tic judge Investigator exclusionary . 8 . Subject 's blood pressure measurement exceed 90th percentile age , sex , height ( base Blood Pressure Levels Age Height Percentile [ boys girl ] ) Screening Visit ( Visit 1 ) Baseline Visit ( Visit 2 ) 9 . Subject known history hypertension 10 . Subject known history symptomatic cardiovascular disease , advanced arteriosclerosis , structural cardiac abnormality , cardiomyopathy , serious heart rhythm abnormality , coronary artery disease , serious cardiac problem may place him/her increase vulnerability sympathomimetic effect stimulant medication . 11 . Subject know family history sudden cardiac death ventricular arrhythmia . 12 . Subject clinically significant ECG clinically significant laboratory abnormality Screening Visit ( Visit 1 ) . 13 . Subject current abnormal thyroid function , define abnormal thyroid stimulate hormone thyroxine Screening Visit ( Visit 1 ) . Treatment stable dose thyroid medication least 3 month permit . 14 . Subject document allergy , hypersensitivity , intolerance amphetamine excipients investigational product . 15 . Subject fail respond , base Investigator judgment , adequate course ( ) ( dose duration ) amphetamine therapy 16 . Subject history suspect substance abuse dependence disorder ( exclude nicotine ) accordance DSMIVTR criterion . Subjects lifetime history amphetamine , cocaine , stimulant abuse and/or dependence exclude . 17 . Subject positive urine drug result Screening Visit ( Visit 1 ) ( exception subject 's current stimulant therapy , ) Baseline Visit ( Visit 2 ) , repeat unless Investigator verify positive result Screening Visit ( Visit 1 ) attribute medication prescribe subject discontinue prior Baseline Visit ( Visit 2 ) . A positive result Screening Visit ( Visit 1 ) attribute prescribed medication require retest negative result Baseline Visit ( Visit 2 ) confirm subject eligibility . 18 . Subject take another investigational product take part clinical study within 30 day prior Screening Visit ( Visit 1 ) . 19 . Subject previously complete , discontinue , withdrawn study . 20 . Subject take medication exclude appropriately wash accord protocol requirement . 21 . Subject required take anticipates need take medication central nervous system effect affect performance , sedate antihistamine decongestant sympathomimetics , monoamine oxidase inhibitor . Stable use bronchodilator inhaler exclusionary . 22 . Subject female pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>